N-ethyl-2-(3-formylindol-1-yl)acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-ethyl-2-(3-formylindol-1-yl)acetamide
• 化学式: C₁₃H₁₄N₂O₂
• mdl: MFCD09755731
• 分子量: 230.26
• InChiKey: WQIWZPKGCTYJMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  51.1
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Malonamic acids and derivatives thereof as thyroid receptor ligands
  申请人：Chiang P. Yuan-Ching

  公开号：US20070173548A1

  公开（公告）日：2007-07-26

  The present invention relates to novel thyroid receptor ligands and, more particularly, relates to malonamic acids and derivatives thereof of Formula I, which are useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss. The present invention also provides methods, pharmaceutical compositions and kits for treating such diseases and disorders.

  本发明涉及新型甲状腺受体配体，更具体地涉及公式I的马隆酰胺及其衍生物，其在治疗肥胖、超重、高脂血症、青光眼、心律失常、皮肤疾病、甲状腺疾病、甲状腺功能减退、甲状腺癌和相关疾病如糖尿病、动脉硬化、高血压、冠心病、充血性心力衰竭、高胆固醇血症、抑郁症、骨质疏松和脱发方面具有用途。本发明还提供了治疗上述疾病和疾病的方法、药物组合物和工具包。
• MALONAMIC ACIDS AND DERIVATIVES THEREOF AS THYROID RECEPTOR LIGANDS
  申请人：Pfizer Products Inc.

  公开号：EP1268404B1

  公开（公告）日：2008-01-02
• US7202275B2
  申请人：——

  公开号：US7202275B2

  公开（公告）日：2007-04-10